Navigation Links
MediciNova Announces Positive Clinical Results From MN-166 Phase II,Multiple Sclerosis Trial

al MRI scans over 12 months of treatment was observed in patients treated with MN-166 compared to placebo, which was the protocol-defined primary endpoint of the study. No clinical or radiological benefit was observed in patients treated with 30 mg per day of MN-166. MN-166 was well tolerated at all doses in this trial. Eighty-nine percent of patients completed the first 12 months of the trial with only mild gastrointestinal side effects observed with MN-166 compared to placebo (3-6% vs. 1-3%, respectively).

The independent Data Safety Monitoring Board (DSMB) has recommended that the trial continue beyond the first year of treatment without modification and was supportive of further clinical evaluation of MN-166 in MS patients.

"We are pleased with the benefit of MN-166 observed in MS patients in this trial; they confirm the results of previous pilot trials of MN-166 in MS patients conducted by Japanese academic investigators," said Yuichi Iwaki, M.D., Ph.D., Executive Chairman and CEO of MediciNova, Inc. "The divergence of clinical benefit and radiological findings suggest that MN-166 may be acting by a different mode of action than current treatments. We will carefully analyze the clinical data with our independent advisors to determine next steps in the development program and to advance this compound into Phase III clinical testing."

In July 2005, MediciNova initiated a randomized, double-blind, placebo-controlled multi-center Phase II clinical trial of MN-166 in MS patients in five Eastern European countries. A total of 297 patients with at least one gadolinium-enhancing lesion on a screening visit MRI scan were randomized to receive placebo or one of two doses of MN-166 (30 or 60 mg per day) in this trial. Safety and efficacy assessments were performed at months 1, 2, 4, 6, 8, 10 and 12 of the trial. Efficacy assessments were based on the evaluation of the cumulative number of active (gadolinium-enhancing (T1) and non-enhancing new/enlargi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/28/2015)... , FARUM, Denmark and ... On July 31, 2015 the US Food and Drug Administration ... of Major Depressive Disorder in adult patients who have failed ... current episode. TMS is a non-invasive technique for stimulating neural ... suffering from Major Depressive Disorder. The procedure has been proven ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de ... PHIA) anunció hoy su participación en el  Congreso ... sus soluciones cardiológicas más recientes y novedosas, entre ... que conectan a las personas y la tecnología ... ayudar a diagnosticar, guiar los tratamientos y permitir ...
(Date:8/27/2015)... Aug. 27, 2015  A recent study by ... Journal, compared the Arthrosurface HemiCAP® Wave implant, which ... an "onlay" design implant for isolated patellofemoral disease. ... function and pain scores, none of the patients ... (OA). However, 53% of the patients in the ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
(Date:8/28/2015)... Madre, CA (PRWEB) , ... August 28, 2015 ... ... solutions to wound center management, Decatur County Memorial Hospital recently transitioned management companies ... model of Wound Center Management for their outpatient wound center. , Transitioning ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately ... the Zoo to celebrate children helping children, a thank you to the many ... Ohio have contributed to the United Methodist initiative to end malaria deaths. , ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published August 19th ... LaRocco has gone through to open a pizzeria in Westchester. Mr. LaRocco was aware ... take several months, but the current process, having already gone on for over a ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for ... subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk ... believe that together, a difference can be made. Walkers can participate in the cause ...
(Date:8/28/2015)... ... 2015 , ... As reported by Medical Daily on August 22 , ... that last for two years, the longest of any cellulite reduction system currently on ... a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director of ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... that the U.S. Department of Defense is funding to ... hospital patients from deadly infections, thanks to recent funding ... and Academic Research (NYSTAR). ,The funding comes as ... to treat, are on the rise. ,The ...
... UK recommendations for the availability of paracetamol, a common painkiller ... to limit the impact of excess doses of paracetamol, which ... drug is highly toxic to the liver in large amounts. ... to a maximum of 32 tablets of 500 mg each ...
... Volker Heussler of the Bernhard Nocht Institute for Tropical Medicine ... the immune system by killing the liver cell occupied by ... man, malarial parasites head to the liver and then to ... how the parasite avoids the immune system. Heussler's team used ...
... study on Rheumatic disease in women has shown that ... who have no genetic predisposition// to the disease. ... chronic inflammation of the joints. The cause of ... environmental factors is thought to trigger the immune system ...
... researchers found that altering the fatty acid ratio found in ... and decrease the amount of omega-6 fatty acids// may reduce ... in the Aug. 1 issue of the journal Clinical Cancer ... to show the impact of diet on lowering an inflammatory ...
... the brain of older patients with atrial fibrillation whether ... therapy// , according to a new study. ... from the University of California, San Francisco, Massachusetts General ... Boston University School of Medicine. ,Using a ...
Cached Medicine News:Health News:Device Can "Battle" Hospital Infections 2Health News:Device Can "Battle" Hospital Infections 3Health News:UK Recommendations On Painkillers Flaunted 2Health News:Altering Fatty Acid Levels in Diet May Reduce Prostate Cancer Growth Rate 2Health News:Risk of Brain Hemorrhage Rises with Old Age 2
Conventional Digitally-Controlled Water Baths...
... consists of two principal components. The AB5000 Console ... blood pumps and can be used either in ... hospitals. The AB5000 Ventricle is a disposable blood ... both ventricles of the heart and is designed ...
... The Dengue virus belongs to the Flavavirus ... commonly throughout the tropics.,Symptoms of Dengue fever ... pain in the back and limbs, lymphadenopathy,maculopapular ... for professional use as an aid in ...
... intracellular parasite Toxoplasma gondii and,may be contracted ... with cat,feces containing oocytes. If a pregnant ... the fetus through the placenta. This can ... of mortality and malformation.,This test is intended ...
Medicine Products: